BTG2 has been reported to be a cancer inhibitor gene and exhibits low levels of expression in tumour tissues, the inhibition of which has been linked with metastasis, invasion and migration of tumour cells.25 Meanwhile, a prior study has also provided an insight suggesting that there is a decrease in BTG levels in pancreatic ductal adenocarcinoma, indicating that BTG2 is the direct target of cooperative miR‐2a, miR‐23a and miR‐27a.14 All of the aforementioned findings were supporting evidence that miR‐27a negatively regulated BTG2 in PC. Here, BTG2 is linked to pachyonychia congenita.